Head to Head Comparison: Atara Biotherapeutics (ATRA) and Its Peers

Atara Biotherapeutics (NASDAQ: ATRA) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Atara Biotherapeutics to similar companies based on the strength of its profitability, dividends, valuation, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Atara Biotherapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atara Biotherapeutics N/A -58.41% -52.64%
Atara Biotherapeutics Competitors -5,342.22% -218.30% -39.92%

Risk & Volatility

Atara Biotherapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Atara Biotherapeutics’ rivals have a beta of 8.67, indicating that their average share price is 767% more volatile than the S&P 500.

Insider & Institutional Ownership

85.6% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Atara Biotherapeutics and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Atara Biotherapeutics N/A -$79.04 million -4.50
Atara Biotherapeutics Competitors $284.49 million $34.10 million 69.48

Atara Biotherapeutics’ rivals have higher revenue and earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations for Atara Biotherapeutics and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atara Biotherapeutics 1 1 3 0 2.40
Atara Biotherapeutics Competitors 882 3256 11746 235 2.70

Atara Biotherapeutics presently has a consensus price target of $26.75, indicating a potential upside of 71.47%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.56%. Given Atara Biotherapeutics’ higher probable upside, equities analysts clearly believe Atara Biotherapeutics is more favorable than its rivals.

Summary

Atara Biotherapeutics rivals beat Atara Biotherapeutics on 9 of the 13 factors compared.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company’s product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company’s T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

What are top analysts saying about Atara Biotherapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Atara Biotherapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit